Navigation Links
Jennerex Appoints James M. Burke, M.D. Vice President, Clinical Research
Date:2/22/2011

wn University and his B.S. in biochemistry and cell biology from the University of California, San Diego. He is the author of more than 10 key publications and presentations detailing the use of gene therapy and oncolytic viruses to treat cancer. He is board certified in hematology, oncology and internal medicine.

About Jennerex

Jennerex, Inc. is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The Company's lead product JX-594 is currently in two Phase 2 clinical trials in patients with primary liver cancer—an international, randomized, Phase 2 clinical trial, and a Phase 2 study of JX-594 in combination with sorafenib. Published studies designed to establish optimal dose levels and the safety profile of JX-594 have shown its ability to selectively target and cause destruction of a variety of common cancer types. JX-594 and other product candidates under development are designed to attack cancer tumors through three diverse mechanisms of action: the lysis of cancer cells through viral replication, the ablation of the blood supply to tumors through vascular targeting and destruction and the stimulation of the body's immune response against the cancer. Jennerex is headquartered in San Francisco and has related research and development operations in Ottawa, Canada and Pusan, South Korea. For more information about Jennerex, please visit www.jennerex.com.


'/>"/>
SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Jennerex and Transgene Enter Into an Exclusive Partnership for the Development and Commercialization of JX-594 for the Treatment of Cancers
2. Jennerex Completes Fully Subscribed Private Placement for Aggregate Gross Proceeds of $8.6 Million
3. Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
4. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
5. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
6. Jennerex Closes $5 Million First Tranche of Series C Financing
7. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
8. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
9. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
10. ALS Therapy Development Institute Appoints Anil Godhwani to Board of Directors
11. Amarin Corporation Appoints Industry Veteran Paul E. Huff as Chief Commercial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... , May 5, 2015  Blueprint Medicines ... of its initial public offering of 9,367,708 shares ... of $18.00 per share, including shares of common ... underwriters of their option to purchase additional shares. ... to Blueprint Medicines were approximately $168.6 million, before underwriting ...
(Date:5/5/2015)... Mich. (PRWEB) May 05, 2015 ... publishing services to develop custom course materials for smaller ... annual enrollments as low as 200 students. , ... a broader range of higher education instructors,” said Jeff ... the country, we can do our part to make ...
(Date:5/5/2015)... May 5, 2015  Renova™ Therapeutics, a biopharmaceutical ... failure and other chronic diseases, has engaged RAND ... designed to reflect the healthcare patterns of multiple ... will be used to characterize the impact the ... on those groups of patients and the overall ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 Franz Inc ... technology, today announced that its flagship product, AllegroGraph, has been ... Graph Database Market Update report. AllegroGraph is a ... the W3C industry standards. Graph databases are skyrocketing in popularity ... according to a recent DBMS ranking by DB-Engines. ...
Breaking Biology Technology:Blueprint Medicines Announces Closing of Initial Public Offering 2Hayden-McNeil Expands Publishing Program to Service Lower Enrollment Courses 2RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate 2RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate 3Bloor Research Positions AllegroGraph as a ‘Champion’ in Burgeoning Graph Database Market 2Bloor Research Positions AllegroGraph as a ‘Champion’ in Burgeoning Graph Database Market 3
... , , SOUTH SAN FRANCISCO, ... ) today announced the sale of 3,489,728 of its ... of approximately $6.5 million, or approximately $1.87 per share, ... The Company intends to use the proceeds from this ...
... LEIDEN, The Netherlands, December 22 Dosage,recommendations for newborns being ... most likely be based on more individual characteristics than,just body ... the Dutch Top,Institute Pharma in which Leiden University (Prof M. ... Tibboel),are represented. , Catherijne Knibbe, clinical ...
... Dec. 21 Ipsogen SA (Alternext: ALIPS) today announced ... tumor grade in chemotherapy prescription has been presented at ... December 9-13, 2009. , The study was conducted ... Using the centre database and a classification tree method, ...
Cached Biology Technology:Poniard Pharmaceuticals Announces $6.5 Million Financing 2Poniard Pharmaceuticals Announces $6.5 Million Financing 3Research: Dosage of Morphine for ill Newborns Still too Imprecise 2Institut Paoli Calmettes and Ipsogen Presented a New Study Supporting the Pivotal Role of Tumor Grade in Chemotherapy Prescription at the 32nd Annual San Antonio Breast Cancer Symposium 2
(Date:4/27/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market, announces that its ... the first week of May, 2015 and will be ... Gino Pereira , Chief Executive ... company as Wocket® enters the consumer market. We would ...
(Date:4/17/2015)... BURNABY, Canada , April 17, 2015 /PRNewswire/ ... projects, growing security concerns, and technological advancement to ... Arabia until 2020   ... " Saudi Arabia Biometric Systems Market Forecast &  Opportunities, 2020 ", biometric ... is projected to register growth at CAGR ...
(Date:4/10/2015)... 10, 2015 Research and Markets ... "Security Competitive Profiles - NEC" report to ... NEC will continue to supply a range of ... with a company focus on the development of a ... Winning opportunities in the Asia-Pacific ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3NEC Security Competitive Profile 2015 2
... of the marine food chain, albatrosses accumulate toxic contaminants ... A new study has found dramatic differences in contaminant ... in different areas of the North Pacific. Researchers also ... in both species over the past ten years. , ...
... scrubbing off and discarding the outer layer of long-grain ... the first time, scientists in Japan have shown that ... significantly lowers blood pressure in rats whose hypertension resembles ... in the March 8 issue of the Journal ...
... a blueprint for boosting anti-cancer drugs' effectiveness and lowering ... sinker onto the drugs. This extra weight makes the ... Chemotherapy drugs often fall short of achieving their full ... the tumor too rapidly, said the scientists from Duke ...
Cached Biology News:Albatross study shows regional differences in ocean contamination 2Albatross study shows regional differences in ocean contamination 3How nice, brown rice: Study shows rice bran lowers blood pressure in rats 2Weighting cancer drugs to make them hit tumors harder 2Weighting cancer drugs to make them hit tumors harder 3Weighting cancer drugs to make them hit tumors harder 4
Request Info...
Mouse monoclonal [3G131] to Desmoglein 1 ( Abpromise for all tested applications). entrezGeneID: 1828 SwissProtID: Q02413...
TCP-1 alpha (H-110)...
Synphilin 1 Immunogen: Synthetic peptide corresponding to residues S(829) L E L N G E K D K D K G R T L Q R T(847) of human Synphilin 1. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: